Congratulation | Qankorey’s distributor established succesfully collaborations with Hospital Sultan Abdul Aziz Shah
Visits:
2024-08-13
In an effort to revolutionize early screening for dementia in Malaysia, Hunan Qankorey, a leading health technology company, through its exclusive local distributor, has partnered with Sultan Abdul Aziz Shah Hospital (HSAAS) to conduct a clinical trial to introduce Malaysia's first One Step Dementia Risk Test Kit.
Left: Ng Lyp Hau, Director, Clotech Sdn Bhd
Right: Associate Professor Dr. Liyana Najwa Binti Inche Mat, Head of Department of Neurology, Faculty of Medicine at Universiti Putra Malaysia
These early screening reagents are expected to revolutionize the way dementia is diagnosed, enabling early screening and intervention, which is crucial for Malaysia's increasingly aging population. Currently, an estimated 8.5% to 11% of older people in Malaysia suffer from dementia.
The exclusive distributor and Sultan Abdul Aziz Shah Hospital formally signed a collaboration agreement (MOA) today in preparation for the research and application of the Alzheimer's early screening reagent in Malaysia.
The Alzheimer's disease early screening reagent has been approved by the Malaysian Medical Device Administration (MDA) and is expected to be provided to hospitals and clinics nationwide. The test provides a non-invasive method for early screening of mild cognitive impairment (MCI) and early-onset Alzheimer's disease by detecting amyloid in urine.